Drug Pipeline

The industry is adjusting to the pandemic, but FDA approvals could dip this year. Several new drugs for atopic dermatitis may get the agency’s green light.

Pre-pandemic momentum helped keep the number of novel therapies approved by the FDA high, and then COVID-19 tested just how fast the pipeline could adjust and expand.

Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.

Negative results for semorinemab have deflated some of the hopes for a tau as a target, although a winning strategy Alzheimer's may involve hitting several targets at once, including tau.

FDA actions for the week ending August 21, 2020, include a hearing set for a drug that could limit weight gain often associated with treatment for serious mental illness.

Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.

In a busy week, FDA approved ground-breaking therapies in hematologic cancers and issued Orphan Drug designations in areas of significant unmet need.

Potential agents to battle inflammation and other processes move through development pipeline.

As several COVID-19 vaccine candidates are now in the late phase of clinical trials, MHE is sharing a few stories that have covered the infamous virus' vaccine development journey.

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Dr. David Ho, who developed the HIV cocktail, has isolated antibodies he says could be used to create treatments for COVID-19.

How real-world evidence will help FDA develop a vaccine.

Heart disease drugs were in the news this week.

The fast-evolving field of precision medicine offers the promise of more effective treatments and better outcomes, and it’s time that we collaborate to keep outdated clinical and reimbursement practices from slowing it down.

Patients with diabetic macular edema whose vision remains impaired even with the best available treatments may soon have a combination therapy.

Drug development in key areas of unmet need hit milestones this week, with Biogen, AstraZeneca, and Jaguar Health announcing regulatory steps with the FDA.

Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.

Here are the top drugs expected to be approved this year and their financial impact.

From breast cancer to prostate cancer, the state of oncology care and how it will evolve.

What to expect for these high-dollar drugs.

The vaccines that could make a big impact on healthcare, from radical new flu vaccines to simplified meningococcal vaccine regimens.

The disease management and insurer initiatives changing the diabetes landscape.

The latest in RA therapies, and what you can expect from the pipeline.

Managed Healthcare Executive asked top experts their predictions for the top game-changing therapies. Here’s what they said.

The biggest drug categories and medications set for approval this year.

Major blockbuster drugs slated for launch in 2019 are expected to have a significant impact on treating certain cancers, diabetes, peanut allergies, and other conditions.

Vaccines are an important part of creating “herd immunity” to keep infectious diseases in check. Here are three vaccine developments that have far reaching implications for public health.

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society, offers a quick overview of current developments as well as a look forward.

Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.